Viral Arthritis Vaccine Market Projected For Strong Expansion Through 2030: Key Trends And Future Outlook
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Viral Arthritis Vaccine Market Forecast: Value Set To Climb From $7.36 Billion To $11.09 Billion
The viral arthritis vaccine market size has seen rapid growth in recent years. It is anticipated to expand from $6.66 billion in 2025 to $7.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. This historical expansion can be attributed to factors such as the history of chikungunya outbreaks, innovations in vaccine platforms, worldwide immunization initiatives, research into zoonotic viruses, and public health preparedness endeavors.
The viral arthritis vaccine market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $11.09 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.8%. Factors driving this growth throughout the projected period include advanced vaccine platforms, the increasing risks posed by arboviruses, expedited clinical trials, increased exposure due to international travel, and the broadening scope of preventive immunization efforts. Key developments expected during this forecast span encompass mRNA-based viral arthritis vaccines, recombinant vector vaccine technologies, multivalent vaccines targeting arthritogenic viruses, agile vaccine design strategies, and enhanced adjuvanted immunogenic formulations.
Get A Free Sample Report With In-Depth Market Insights:
Viral Arthritis Vaccine Market Development Factors: What’s Supporting Demand?
The increasing occurrence of mosquito-borne viral infections is anticipated to stimulate the expansion of the viral arthritis vaccine market moving forward. These infections are illnesses transmitted to humans through the bite of infected mosquitoes, encompassing chikungunya, Zika, and dengue viruses. Such infections can manifest as fever, joint pain, rash, and in some instances, enduring complications like viral arthritis. The rise in mosquito-borne viral infections is attributed to climate change, which fosters warmer temperatures and altered rainfall patterns, thus enlarging mosquito habitats and breeding periods. A viral arthritis vaccine aids in curbing mosquito-borne viral infections by preventing both infection and the progression of diseases stemming from viruses that cause joint inflammation, thereby reducing transmission risk and the disease burden in affected populations. For instance, in 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported over 7.6 million cases globally by April. This total tripled the number recorded during the equivalent period in 2023, with transmission continuing to extend across more than 90 countries. Hence, the growing incidence of mosquito-borne viral infections is propelling the growth of the viral arthritis vaccine market.
Viral Arthritis Vaccine Market Segment Outlook: Which Categories Are Growing Fastest?
The viral arthritis vaccine market covered in this report is segmented –
1) By Type: Viral Arthritis Vaccine, Live; Viral Arthritis Vaccine, Inactivated
2) By Virus Targeted: Chikungunya Virus; Rubella Virus; Parvovirus; Other Viral Arthritis-Causing Viruses
3) By Application: Farms; Individual
4) By End-User: Hospitals And Clinics; Vaccination Centers; Homecare; Government Programs
Subsegments:
1) By Viral Arthritis Vaccine, Live: Single Dose; Combination Dose; Recombinant Live Vaccine
2) By Viral Arthritis Vaccine, Inactivated: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Adjuvanted Inactivated Vaccine
Viral Arthritis Vaccine Market Transformation Trends: What Innovations Are Driving Change?
Leading companies operating within the viral arthritis vaccine market are prioritizing the development of innovative vaccine candidates, such as live-attenuated and next-generation chikungunya vaccines, to address the escalating demand for effective prevention of viral-induced joint pain and persistent arthritic complications, particularly among vulnerable groups. These live-attenuated and next-generation chikungunya vaccines are sophisticated formulations designed to avert chikungunya virus infection by stimulating powerful and lasting immune responses. Live-attenuated vaccines achieve this by using weakened forms of the virus to closely mimic a natural infection and provide durable protection, while next-generation vaccines utilize modern platforms like viral vectors, recombinant proteins, or novel attenuation technologies to improve safety, immunogenicity, and wider applicability across populations. For example, in June 2025, Bavarian Nordic A/S, a Denmark-based biotechnology company, initiated a Phase 3 clinical study of its chikungunya vaccine in children, aiming to extend protection to pediatric populations in endemic regions where exposure early in life can lead to significant disease burden. This advancement to late-stage clinical evaluation demonstrates increasing confidence in the vaccine’s safety and immunogenicity profile and highlights ongoing efforts to broaden age indications, strengthen population-level immunity, and mitigate the global long-term impact of chikungunya-associated viral arthritis.
Viral Arthritis Vaccine Market Top Companies Driving Competitive Growth
Major companies operating in the viral arthritis vaccine market are Bavarian Nordic A/S, Serum Institute of India Private Limited, Valneva SE, Bharat Biotech International Limited, Panacea Biotec Ltd., The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd.
View The Full Viral Arthritis Vaccine Market Report:
Viral Arthritis Vaccine Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the viral arthritis vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral arthritis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
